Trade Quanterix Corp - QTRX CFD

Quanterix Company profile

About Quanterix Corp

Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. It also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. It provides services through its Simoa Accelerator Laboratory.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Quanterix Corp revenues increased 28% to $110.6M. Net loss increased 83% to $57.7M. Revenues reflect Product revenue segment increase of 84% to $81.1M. Higher net loss reflects Selling, General & Administrative Expens increase of 55% to $79M (expense), Research & Development Expense - Balanci increase of 37% to $26.2M (expense).